000118971 001__ 118971
000118971 005__ 20240319081012.0
000118971 0247_ $$2doi$$a10.1002/cmdc.202200244
000118971 0248_ $$2sideral$$a130152
000118971 037__ $$aART-2022-130152
000118971 041__ $$aeng
000118971 100__ $$0(orcid)0000-0001-5201-0874$$aRedrado, Marta
000118971 245__ $$aTunable Emissive Ir(III) Benzimidazole-quinoline Hybrids as Promising Theranostic Lead Compounds
000118971 260__ $$c2022
000118971 5060_ $$aAccess copy available to the general public$$fUnrestricted
000118971 5203_ $$aBioactive and luminescent cyclometallated Ir(III) complexes Ir(ppy)2L1]Cl (1) and Ir(ppy)2L2]Cl (2) containing a benzimidazole derivative (L1/L2) as auxiliary mimic of a nucleotide have been synthesised. The emissive properties of both complexes are conditioned by the nature of L1 and L2, rendering an orange and a green emitter respectively. Both are highly emissive with quantum yield increasing in absence of oxygen up to 0.26 (1) and 0.36 (2), suggesting their phosphorescent character. Antiproliferative activity against lung cancer A549 cells increased up to 15 times upon irradiation conditions, reaching IC50 values in the nanomolar range (0.3±0.09 µM (1) and 0.26±0.14 µM (2)) and pointing them as good PSs candidates for photodynamic therapy via 1O2 generation. Cellular biodistribution analysis by fluorescence microscopy suggest the lysosomes as the preferential accumulation organelle. Time-resolved studies showed a greatly increased cellular emission lifetime compared to the solution values, indicating binding to macromolecules or cellular structures and restriction of collision and vibrational quenching.
000118971 536__ $$9info:eu-repo/grantAgreement/ES/DGA-FSE/E07-20R$$9info:eu-repo/grantAgreement/ES/MCIU/RED2018-102471-T$$9info:eu-repo/grantAgreement/ES/MCIU/RTI2018-097836-J-I00$$9info:eu-repo/grantAgreement/ES/MICINN/RYC-2018-025872-I$$9info:eu-repo/grantAgreement/ES/MICINN/PID2019-104379RB-C21-AEI-10.13039-501100011033
000118971 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000118971 590__ $$a3.4$$b2022
000118971 592__ $$a0.711$$b2022
000118971 591__ $$aPHARMACOLOGY & PHARMACY$$b125 / 278 = 0.45$$c2022$$dQ2$$eT2
000118971 593__ $$aPharmacology, Toxicology and Pharmaceutics (miscellaneous)$$c2022$$dQ1
000118971 591__ $$aCHEMISTRY, MEDICINAL$$b33 / 60 = 0.55$$c2022$$dQ3$$eT2
000118971 593__ $$aBiochemistry$$c2022$$dQ2
000118971 593__ $$aDrug Discovery$$c2022$$dQ2
000118971 593__ $$aOrganic Chemistry$$c2022$$dQ2
000118971 593__ $$aPharmacology$$c2022$$dQ2
000118971 593__ $$aMolecular Medicine$$c2022$$dQ3
000118971 594__ $$a5.6$$b2022
000118971 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000118971 700__ $$aMiñana, Miriam
000118971 700__ $$aCoogan, Michael P.
000118971 700__ $$0(orcid)0000-0003-0553-0695$$aGimeno, M. Concepción
000118971 700__ $$0(orcid)0000-0002-1218-7218$$aFernández Moreira, Vanesa$$uUniversidad de Zaragoza
000118971 7102_ $$12010$$2760$$aUniversidad de Zaragoza$$bDpto. Química Inorgánica$$cÁrea Química Inorgánica
000118971 773__ $$g17 (2022), [1-11]$$pChemMedChem$$tCHEMMEDCHEM$$x1860-7179
000118971 8564_ $$s2061320$$uhttps://zaguan.unizar.es/record/118971/files/texto_completo.pdf$$yVersión publicada
000118971 8564_ $$s2927804$$uhttps://zaguan.unizar.es/record/118971/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000118971 909CO $$ooai:zaguan.unizar.es:118971$$particulos$$pdriver
000118971 951__ $$a2024-03-18-15:17:19
000118971 980__ $$aARTICLE